Physician profile
Alain Eid
NPI 1639174352
$18,493.38
in general payments reported to CMS, 2019-2025
49 companies · $709 in 2025
The $709 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,378 · 2020: $8,346 · 2021: $4,431 · 2022: $1,743 · 2023: $1,124 · 2024: $761 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,593.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $8,258.87 | 2019-2025 | Nucala |
| Intuitive Surgical, INC. | $3,283.46 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,100.76 | 2019-2025 | Breztri, Fasenra, Imfinzi |
| Actelion Pharmaceuticals US, INC. | $587.08 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.39 | 2019-2023 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $510.75 | 2019-2025 | |
| Grifols USA, LLC | $346.23 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $325.54 | 2019-2021 | |
| Genzyme Corporation | $317.62 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $316.22 | 2021-2025 | Dupixent |
| United Therapeutics Corporation | $298.68 | 2019-2024 | Tyvaso, Orenitram, Remodulin |
| E.R. Squibb & Sons, L.L.C. | $262.26 | 2019-2023 | Eliquis |
| Inspire Medical Systems, INC. | $197.91 | 2024-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $177.77 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $176.92 | 2019-2025 | Winrevair, Zerbaxa |
Show all 47 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alain Eid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.